Diamorphine being added to list of opioids (Part B): Notice of amendment
Date: January 14, 2022
This notice of amendment is to notify stakeholders that Health Canada has amended Part B of the List of Opioids.
Specifically, we have added the active ingredient "diamorphine" to Part B of the opioids list. Opioids included in this list are subject to market authorization terms and conditions requiring the submission of a Canadian-specific opioid targeted risk management plan.
The listing in Part B now reads:
- drugs intended for human use containing any of the following active ingredients: diamorphine
- including (but not limited to): diamorphine hydrochloride; diacetylmorphine hydrochloride
- qualifier: none
- effective date: January 14, 2022
If you have any questions on this amendment, please contact the regulatory project management section at:
Marketed Pharmaceuticals Bureau
Marketed Health Products Directorate
Address Locator 1912A
200 Eglantine Dr
Ottawa ON K1A 0K9
- Date modified: